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Investigation of the effect of Stalanev (Stavudine, Lamivudine and 
Nevirapine) treatment on plasma lactate levels in adults attending 
Beatrice Road and Wilkins Infectious Diseases Hospital 
Opportunistic Infections Clinics in Harare, Zimbabwe
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Abstract
Main Objective: To evaluate the effect o f Stalanev (Stavudine, Lamivudine and Nevirapine) treatment on 
plasma lactate levels in adults attending Beatrice Road Infectious Diseases Hospital and Wilkins Infectious 
Diseases Hospital Opportunistic Infections Clinics in Harare,
Design: Prospective cohort study carried out between January and May 2011
Setting: Beatrice Road and Wilkins Infectious Diseases Hospital Opportunistic Infections Clinics in Harare, 
Zimbabwe.
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Participants: A convenience sample of 180 ART naive HIV infected adults aged 20-68 years who were about 
to be initiated on STALANEV were recruited.
Results: The mean plasma lactate at baseline was 1.57 mmol/L (SD 0.43). After two months on STALANEV, 
25 participants (13.9%) had hyperlactatemia and the mean plasma lactate level was 1.99mmol/L (SD 0.49). 
At four months follow up, 98 participants (54%) had hyperlactatemia and the mean plasma lactate level was 
2.65 mmol/1 (SD 0.55). Mean plasma lactate levels increased significantly from baseline to 2months follow 
up and from 2months follow up to 4months follow up (p<0.001). None of the participants developed lactic 
acidosis (plasma lactate >3.5) after two months of follow up but 14 (7.8%) developed mild lactic acidosis and 
three (1.7%) had moderate lactic acidosis after four months on STALANEV
Conclusions: Our findings are in agreement with those of other studies that reported that treatment with 
STALANEV leads to hyperlactatemia thereby posing a risk for the development o f lactic acidosis in patients. 
In the absence of alternative regimens, we recommend routine monitoring o f plasma lactate levels on all 
patients on STALANEV in Zimbabwe.
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Background
HIV/AIDS has become a significant public health 
problem in Zimbabwe, threatening the socio-economic 
fibre of the country and placing a tremendous strain on 
health delivery capacity. Although antiretroviral 
therapy (ART) roll out has reduced morbidity and 
mortality due to HIV/ AIDS, new challenges have 
arisen because of the development of metabolic 
changes induced by ART. These include impaired 
glucose metabolism, insulin resistance, lactic acidosis, 
osteopenia and dyslipidaemia1. Stavudine has been 
reported to cause mitochondrial toxicity that manifests 
as lactic acidosis in the majority of patients.2
Consequent to these adverse events, the WHO has 
recommended phasing out of stavudine in all ART 
regimens.3 However, the stavudine-containing first- 
line regimen is still widely used in most resource 
constrained countries including Zimbabwe. There is a 
paucity of studies exploring the effect of stavudine- 
containing antiretroviral therapy on plasma lactate 
levels in the Zimbabwean population. Thus, the present 
study set to investigate the impact of a stavudine- 
containing ARV first-line regimen on plasma lactate 
levels and to ascertain other risk factors associated with 
hyperlactataemia in these patients.
Methodology
In this prospective cohort study, 180 consenting HIV­
positive but ART naive adult patients who were about 
to be initiated on STALANEV(stavudine, lamivudine 
and nevirapine) at Beatrice Road Infectious Diseases 
Hospital (BRIDH) and Wilkins Infectious Diseases 
Hospital (W ID H ) opportunistic infections (OI) clinics 
in Harare, Zimbabwe were enrolled into the study. 
N ine ty  e lig ib le  p a rtic ip a n ts  w ere en ro lled  
consecutively from each centre over a period of two 
weeks. Hypertensive patients and those with a self 
reported history of hypoglycaemia, anti tuberculous 
treatment or any other long term drug therapy were 
excluded as were those with baseline hyperlactatemia.
Three millilitres whole blood samples were collected 
with minimum venostasis into a fluoride oxalate
vacutainer tube from each eligible participant. Plasma 
lactate levels were determined prior to ART initiation 
(baseline) and for the next four months at 2 monthly 
intervals. Blood samples were collected after each 
participant had rested for at least 20 minutes and blood 
samples from BRIDH were immediately placed on an 
ice bath for transportation to WIDH laboratory where 
they were centrifuged to harvest plasma within 30 
minutes o f collection.
Plasma lactate analysis was performed on the 
Selectra E analyzer using an ABX Pentra Lactic Acid 
commercial kit supplied by HORIBA ABX (United 
Kingdom). In this assay L-lactate is metabolised to 
pyruvate in the presence o f lactate oxidase triggering 
the release of hydrogen peroxide, which reacts with 4- 
am inoantipyrine and N -ethyl-N -sulfopropyl-m - 
anisidine (ESPAS) in the presence o f peroxidase to 
form a coloured complex, quinoneimine. The intensity 
of the colour formed is measured at 505nm and is 
proportional to the amount o f lactate present in the 
sample. All lactate assays were processed immediately 
after separation of plasma.
Ethical approval was granted by the University of 
Zim babw e's College o f Health Sciences and 
Parirenyatw a Hospital Jo int Research Ethics 
Committee. Permission to access patients from BRIDH 
and WIDH OI clinics and to perform lactate assays was 
granted by the City of Harare Directorate of Health 
Ethics Committee. All participants gave written 
informed consent and completed a questionnaire 
eliciting demographic and general health status. 
Baseline CD4 counts were accessed from eligible 
participants' clinic records.
Results
The participants' ages ranged from 20-68 years with a 
median of 36.6 years (sd 9.8) and they were all 
successfully followed up to the conclusion of the study. 
The 180 participants comprised 114 females (63.3%). 
Baseline CD4 counts ranged from 1 l-205cells/qL 
(median 148) and 97.7% (n = 176) of the participants 
had CD4 counts less than 200 cells/pl. The majority of
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the participants 68.9% (n=154) were in WHO stage 3 ot' 
HIV disease and 12.9% (n=23) were in stage 2.
Figure 1: Plasma lactate levels at baseline, after 
2months and after 4months follow-up. (n—l HQ fo r  each 
timeline
4
E2
Figure I, summarises plasma lactate levels at each of 
the three stages when blood samples were drawn. 
Baseline plasma lactate levels ranged from 0.6 2.5 
mmol/L with a mean of 1.57mmoI/L (sd 0.43). After 
2months on STALANEV the mean plasma lactate was 
1.99mmol/L (sd 0.49) and 2.65mmol/L (sd 0.55) after 
4months on treatment. There was a statistically 
significant increase in plasma lactate from baseline to 
2months on STALANEV and from 2months to 
4months on therapy (p<0.001).
The proportion o f participants with hyperlactatemia 
increased statistically significantly (p<0.001) from 
2months to 4months on treatment with STALANEV. 
After two months on STALANEV, 13.9% (n=25) of the 
participants had hyperlactatemia defined as a plasma 
lactate above 2.5mmol/L. The incidence of participants 
with hyperlactatemia increased to 54% (n =98) at the 
conclusion of the study after follow up and 7.8% 
(n=14) had developed mild lactic acidosis defined by 
plasma lactate levels above 3.5mmol/L. O f these 14 
participants, only 1.7% (n=3) developed moderate 
lactic acidosis with plasma lactate levels above 
3.9mmol/L. There was no statistically significant 
difference in the incidence rates between males (53% 
n=35) and females (55% n=63) (p>0.05).
Univariate linear regression indicated that a low CD4 
count was a statistically significant determinant o f the 
risk of developing hyperlactatemia (p<0.001) whereas 
the HIV/AIDS disease stages 3 and 4 weakly 
determined hyperlactatemia risk (p=0.043). Neither 
age nor gender were risk factors o f developing 
hyperlactatemia in the present study.
Discussion
T his s tudy  co n firm s  a h igh in c id e n ce  o f  
hyperlactatemia in patients treated with STALANEV 
(a stavudine containing regimen). The finding is 
agreement with other studies done in Botswana4, South 
Africa2 5 and U ganda6 which reported similar findings. 
Management of symptomatic lactic acid alterations 
involves treatment interruption and supportive care or 
where possible, switching to an alternative formulary. 
The natural history of hyperlactataemia is still 
unknown, and it is uncertain whether asymptomatic 
patients with increased lactate concentrations are at 
increased risk of developing lactic acidosis.
Mild-to-moderate, asymptomatic hyperlactataemia 
h as  b e e n  f r e q u e n tly  r e p o r te d  in h u m an  
immunodeficiency virus (HlV)-infected patients 
treated with nucleoside reverse transcriptase inhibitors, 
with an estimated prevalence between 15% and 35% in 
Caucasian populations.8 Prevalence rates have been 
reported to be higher in Black women9- a finding 
confirmed by the present study. Symptomatic, severe 
hyperlactataemia and lactic acidosis on the other hand, 
are less common, with an incidence ranging from 1.7 to 
25.2 cases per 1000 person-years of antiretroviral 
treatment, but are associated with a remarkable 
mortality rate, which varies from 30% to 60%.‘° " In the 
present study, only 1.7% (n=3) participants developed 
moderate hyperlactatemia and were referred for 
clinical management.
There was a 20% and a 59% rise in mean plasma 
lactate levels from baseline to two months and from 
baseline to four months on treatment respectively. It is 
likely that severe lactic acidosis would have been 
observed if the participants had been followed up for a 
longer duration. Stavudine contained in the 
STALANEV regimen has been previously reported as 
the precipitating agent due mitochondrial toxicity 
effects.46
In the present study, the CD4 count and HIV/AIDS 
disease stage were significant predictors of the risk 
developing hyperlactatemia. Age and gender were not 
predictive of developing hyperlactatemia. This finding 
was at variance with literature which reports females, a 
higher body mass index and advanced age as risk 
factors of developing hyperlactatemia.4'6 However in 
the present study mean plasma lactate levels after 
4months follow up were higher in female participants 
with a mean of 2.67 mmol/L (sd 0.54) compared to that 
for male participants with a mean of 2.61 (sd 0.57). The 
difference was however not statistically significant 
(p>0.05). Though not demonstrated in the present 
study, the mechanism for the sex difference in rates of 
hyperlactatemia rates is still not clearly elucidated. 
However, plausible explanations include possible sex- 
linked mitochondrial genetic differences which could 
increase females' susceptibility or the predisposition of 
obese women to hepatic steatosis, which may increase 
their risk.12
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In resource constrained settings, challenges in the 
d iagnosis and m anagem ent o f  sym ptom atic  
hypcrlactatemia remain because estimation o f plasma 
lactate concentration is largely unavailable routinely. 
When available in private facilities, the cost is often 
beyond the reach of many. Clinical diagnosis o f lactic 
acidosis is challenging because o f nonspecific 
symptoms and may be confused for symptoms of 
malaria or gastroenteritis.
The weaknesses of the present study however include 
the limited follow up period which made it difficult to 
determine medium to long term adverse reactions if 
any. It could also have been ideal to compare the 
incidence rates o f hypcrlactatemia between groups on 
first line regimens without stavudinc. Finally, the data 
gathered for risk factors determination could also have 
included factors such as the body mass index.
Conclusions
Although Stavudine is no longer recommended as a 
first line treatment agent, its use has continued in 
resource constrained settings because of relatively 
lower production costs. Policy makers thus need to 
prioritise availability of alternative regimens if 
mortality rates due metabolic complications are to be 
reduced. These toxicides related to antiretroviral 
therapy also make long-term compliance to therapy 
difficult for patients.
However, because the current formulary restrictions 
appear unlikely to change soon, health providers in 
resource-poor countries must familiarise with the 
common adverse events associated with long term anti 
viral therapy and must understand how to manage them 
with what is locally available.
Alternatively, routine plasma lactate assays could be 
introduced at affordable cost in state institutions to 
allow routine scheduled monitoring of patients. This 
could be an affordable option for resource constrained 
settings since point-of-carc devices which provide 
simple, accurate measurements of lactic acid levels at 
relatively low cost, arc now available. Use of these 
devices would greatly improve clinical decision­
making.
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